Good day, ladies and gentlemen, and welcome to the Q4 2018 Medical Properties Trust earnings call. At this time, our participants are in listen-only mode. Later, we conduct a question-and-answer session. Instructions will follow at that time. If anyone should require operator assistance, please press star then the zero key on your touchtone telephone. As a reminder, this call is being recorded. I would now like to introduce your host for today's conference, Charles Lambert. Sir, you may begin.
Thank you. Good morning, everyone. Welcome to the Medical Properties Trust conference call to discuss our fourth quarter and year-end 2018 financial results. With me today are Edward K. Aldag Jr., Chairman, President, and Chief Executive Officer of the company, and Steven Hamner, Executive Vice President and Chief Financial Officer. Our press release was distributed this morning and furnished on Form 8-K with the Securities and Exchange Commission. If you did not receive a copy, it is available on our website at www.medicalpropertiestrust.com in the investor relations section. Additionally, we're hosting a live webcast of today's call, which you can access in that same section. During the course of this call, we will make projections and certain other statements that may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause our financial results and future events to differ materially from those expressed and/or underlying such forward-looking statements. We refer you to the company's reports filed with the Securities and Exchange Commission for a discussion of the factors that could cause the company's actual results or future events to differ materially from those expressed in this call. The information being provided today is as of this date only, and except as required by the federal securities laws, the company does not undertake a duty to update any such information. In addition, during the course of the conference call, we will describe certain non-GAAP financial measures which should be considered in addition to, and not in lieu of, comparable GAAP financial measures.
Please note that in our press release, Medical Properties Trust has reconciled all non-GAAP financial measures to the most directly comparable GAAP measures in accordance with Reg G requirements. You can also refer to our website at www.medicalpropertiestrust.com for the most directly comparable financial measures and related reconciliations. I will now turn the call over to our Chief Executive Officer, Ed Aldag.
Thank you, Charles, and thank all of you for listening in today. For 2018, MPT achieved a total shareholder return of more than 25%, compared to a - 4.5% for the MSCI US REIT Index. Our two-year total shareholder return was more than 50%, compared to the SNL US REIT Healthcare Index of 6% and less than 0.5% for the MSCI US REIT Index. For the 10-year total shareholder return, MPT ranked number one for all healthcare REITs with a 445% return, which was more than 2.5x that of the SNL US REIT Healthcare Index. During 2018, MPT had another year of milestones and records.
We once again saw the value of our portfolio validated through multiple and exciting transactions, including our highly valued joint venture in Germany with the Primonial Group, the successful buyout of our equity ownership in Ernest Health, and several other profitable exits, such as the sale of North Cypress Medical Center to HCA. These and other 2018 transactions provided record proceeds of $1.5 billion, of which more than $500 million of those proceeds were over and above our original investment. The proceeds were used to reduce debt and to put MPT in prime position for accretive capital deployment in 2019, like that of the transaction in Australia we just announced. We were pleased to kick off 2019 with our announcement last week of our agreement to acquire 11 Australian hospitals from Healthscope. Since our inception, Australia was a location with which we have targeted for growth.
Like other European countries where we have expanded into, Australia has a healthcare system that is similar to the United States. Healthcare in Australia is among the best in the world, and we are delighted to add these quality Healthscope assets to our portfolio. We've been watching and analyzing the Healthscope assets for more than 10 years now. The portfolio of 11 Healthscope hospitals are truly some of the finest hospitals in Australia. Of the 11 facilities, eight are general acute care hospitals, representing 86% of our total investment. One is a rehab hospital representing 6%, and two are psychiatric facilities representing 7%. They're primarily located along the East Coast, concentrated around Sydney and Melbourne, and in Perth on the West Coast. We've worked directly with the current management team of Healthscope since late summer of 2018 and have been working with Brookfield since the early part of the summer.
We are excited to team up with Brookfield on this transaction and look forward to growing this portfolio with them. 2018 included continued work on exciting construction developments of over $187 million with Surgery Partners and Circle Health, the latter providing another milestone as the first of its kind private, standalone, inpatient rehabilitation hospital in the United Kingdom. MPT continues to be the leader in acute care real estate and has amassed approximately a $10 billion pro forma gross assets with 30 different operators now spanning three continents. Our existing portfolio also continued to perform well. With this quarter's reporting, we added 10 properties to our same-store reporting. All of the additions to the same-store reporting were general acute care hospitals. Our same-store total portfolio EBITDARM coverage for the trailing 12 months Q3 2018 is 3.1 x, which represents a 10% increase year-over-year.
Same-store acute care EBITDARM coverage is 3.6 x, which represents a 12% increase year-over-year. Inpatient rehabilitation EBITDARM coverage increased to 1.9 x, which represents a 2.5% year-over-year coverage improvement. U.S. IRFs represent about 4.6% of our total portfolio. LTAC EBITDARM coverage decreased to 1.5 x, which represents a 7.4% year-over-year decline. It's important to note that this coverage decline is driven by one facility whose EBITDARM coverage declined from over 9x to a still very strong coverage of 5x . LTACs represent approximately 3% of our total portfolio. The United States represents 77% of the total portfolio. Acute care hospitals continue to make up the bulk of our investments domestically at 80%, which is right in line with our target range. It is an important reminder that approximately 93.6% of our same-store portfolio is master lease, cross-defaulted, or includes a parent guarantee.
MPT has never been in a stronger position than the present, as we continue to grow in size and reputation as the global leader in hospital real estate and the industry's preeminent source of capital. We are actively engaged in billions of dollars of domestic and international acquisitions, with more opportunities coming our way. Steve?
Thank you, Ed. On our last quarter's call, we reported that we had completed the capital and portfolio repositioning strategy that we had been focused on for more than a year, resulting in record profitability, liquidity, and financial flexibility, along with an actionable 2019 acquisition pipeline of $2.0 billion. Since then, our acquisition expectations have grown even further, and last week, we demonstrated the strength of that pipeline by announcing agreements to acquire and expand 11 premier hospitals in Australia for as much as $1.2 billion. We'll focus on our outlook for 2019 momentarily. First, I'll review the fourth quarter and full year 2018 results. As expected this morning, we reported normalized FFO of $0.31 per diluted share for the fourth quarter of 2018 and $1.37 for the year.
These annual results do not, of course, include approximately $671 million in gains on the sale of real estate, including a $1.4 million fourth-quarter true-up of the previously completed German joint venture transaction. The only material adjustment from Nareit FFO to normalized FFO was a fourth quarter $4.4 million tax valuation adjustment caused by the continued profitability of our taxable investments. We have previously noted that our estimates provide for general and administrative expenses to be about 9.5% of total revenue. However, we now report revenue from our joint venture assets through the other income line, making prior periods not comparable. For 2018, this revenue approximated $32 million. Moreover, non-cash straight-line rent adjustments during the year reduced revenue by a further $17.5 million. Finally, in 2018, we adopted new accounting policies that reclassified about $6.2 million to G&A.
With these movements, our 2018 G&A represents about 8.9% of comparable revenue. Going forward, we remain confident in our estimates of 9%-9.5% G&A. Before moving on to the updates to our 2019 estimates, I will point out that in December and January, in anticipation of capital needs for our Australian and other likely acquisitions, we activated our $750 million at-the-market equity program and sold approximately 11.9 million shares at an average price of $16.75, for about $200 million in proceeds. Recently, as a result, we had cash balances approximating $900 million, along with a $1.3 billion availability under our revolving credit facility. Given our estimate of in-place EBITDA and outstanding borrowings, our current net debt-to-EBITDA ratio approximates 4.4 x. This morning, we reported that we have increased our 2019 acquisitions expectations by about $500 million-$2.5 billion over our estimate from last quarter.
Consequently, we now estimate that upon completion of the $2.5 billion in expected 2019 acquisitions, our annualized in-place normalized FFO will be about $1.54 per share. Last quarter, our estimate was for approximately $1.50 per share. Built into last quarter's $1.42-$1.46 calendar 2019 normalized FFO estimate was an assumption of a late December acquisition that is now not included in our 2019 estimates. However, due to the growing pipeline, we are maintaining our $1.42-$1.46 calendar 2019 normalized FFO estimate. The calendar year estimate is, of course, sensitive to timing, and we intend to periodically update our estimates as we gain clarity into likelihood of closings. We continue to estimate that the blended GAAP yield of our 2019 acquisitions will fall between 7.5% and 8.5%. To be clear, that is not a range of targeted deal terms, but an average portfolio yield weighted by investment value.
We also continue to expect that nominal capitalization rates will likely be lower in areas outside the United States, where the cost of capital is similarly lower than in the U.S. The Australian opportunity is a good example wherein we invest to achieve yields substantially above our cost of capital. Just to clarify, this investment will be strongly and immediately accretive for our shareholders. Importantly, certain investments can also deliver intangible value that leads directly to even lower cost of capital and higher long-term FFO. These intangibles include diversification from geographic, tenant, and credit perspectives, extension of our portfolio average lease terms, improvement of MPT's own credit ratings and borrowing cost, and attraction of other forms of long-term permanent and inexpensive equity-like capital. The best recent example of this last benefit is the creation of $600 million in virtually free capital through our German joint venture.
We do not focus solely on the year one cash capitalization rate when we underwrite a potential acquisition. We will continue to grow Medical Properties Trust as the unchallenged and sustainable global leader in hospital real estate finance. This requires that rather than simply building a collection of stand-alone leases, we create a portfolio of many assets, providing diversity in geographies, operators, and property types that create predictable inflation-protected cash returns for our shareholders. Along with the initial cap rates and immediate accretion, we consider all of these characteristics and their effects on our portfolio taken as a